Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group.Nyla A. Heerema, Fatih M. Uckun, Harland N. Sather et al.|PubMed|1999Cited by 105
Prospective Randomized Trial Between Two Doses of Granulocyte Colony-Stimulating Factor After Ifosfamide, Carboplatin, and Etoposide in Children With Recurrent or Refractory Solid Tumors: A Children's Cancer Group ReportMitchell S. Cairo, Gregory H. Reaman, Sharon Frierdich et al.|The American journal of pediatric hematology/oncology|2001Cited by 56
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.Francisco Bracho, Mitchell S. Cairo, Mark Krailo et al.|PubMed|2001Cited by 17
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Association of Chromosome Arm 9p Abnormalities With Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer GroupNyla A. Heerema, Fatih M. Uckun, Harland N. Sather et al.|Unknown|2016Cited by 0